1.35 0 (0%) | 12-30 00:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 29.49 | 1-year : | 34.44 |
Resists | First : | 25.25 | Second : | 29.49 |
Pivot price | 23.31 | |||
Supports | First : | 20.93 | Second : | 18.26 |
MAs | MA(5) : | 23.99 | MA(20) : | 23 |
MA(100) : | 18.15 | MA(250) : | 16.14 | |
MACD | MACD : | 1.3 | Signal : | 1.4 |
%K %D | K(14,3) : | 73.3 | D(3) : | 75.2 |
RSI | RSI(14): 60.8 | |||
52-week | High : | 25.25 | Low : | 1.22 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ GMTX ] has closed below upper band by 38.1%. Bollinger Bands are 7.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 24.65 - 24.75 | 24.75 - 24.85 |
Low: | 23.03 - 23.14 | 23.14 - 23.24 |
Close: | 23.76 - 23.93 | 23.93 - 24.09 |
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Mon, 25 Mar 2024
Gemini Therapeutics (NASDAQ:GMTX) Sets New 1-Year High at $60.96 - MarketBeat
Tue, 19 Mar 2024
Gemini Therapeutics (NASDAQ:GMTX) Hits New 12-Month High at $67.76 - MarketBeat
Fri, 21 Jul 2023
Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Gemini Therapeutics, Inc. (GMTX) Investigation - AccessWire
Wed, 10 Aug 2022
Gemini Therapeutics Announces Reverse Merger Pact With Hematology-Focused Company - Yahoo Finance
Wed, 10 Aug 2022
WilmerHale Represents Gemini Therapeutics in Merger with Disc Medicine - WilmerHale
Wed, 12 May 2021
Is Gemini Therapeutics Inc (GMTX) Stock Worth a Buy Wednesday? - InvestorsObserver
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 43 (M) |
Shares Float | 11 (M) |
Held by Insiders | 0.2 (%) |
Held by Institutions | 87.5 (%) |
Shares Short | 1,470 (K) |
Shares Short P.Month | 1,510 (K) |
EPS | -1.58 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 2.41 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -19.5 % |
Return on Equity (ttm) | -35.4 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -0.94 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -43 (M) |
Levered Free Cash Flow | -23 (M) |
PE Ratio | -15.18 |
PEG Ratio | 0 |
Price to Book value | 9.92 |
Price to Sales | 0 |
Price to Cash Flow | -24.39 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |